留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码
x 关闭 永久关闭

应中央军委要求，2022年9月起，《药学实践杂志》将更名为《药学实践与服务》，双月刊，正文96页；2023年1月起，拟出版月刊，正文64页，数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿！

肠道微生态与炎症性肠病

何丽娟,  张军东,  安毛毛,  姜远英

downloadPDF
文章导航 > 药学实践与服务  > 2015 >  33(5): 385-388,422
何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
引用本文: 何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
shu
HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
Citation: HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
shu

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001
  • 1.

    第二军医大学药学院新药研究中心, 上海 200433

  • 2.

    同济大学附属第十人民医院, 上海 200072

  • 3.

    同济大学医学院, 上海 200092

Gut microbiota and inflammatory bowel disease

  • 1.

    New Drug Research and Development Center, School of Pharmacy, Second Military Medical University, Shanghai 200433, China

  • 2.

    Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai 200072, China

  • 3.

    School of Medicine, Tongji University, Shanghai 200092, China

  • 摘要: 炎症性肠病(inflammatory bowel disease,IBD)是一组病因未明、发病机制亦不明确的慢性肠道炎症性疾病,主要包括克罗恩病(Crohn's disease,CD)和溃疡性结肠炎(ulcerative colitis,UC)。近几十年的研究结果认为,其发病是环境、易感基因和肠道微生态3个要素相互作用的结果,且这些要素使IBD成为一种适合研究宿主与肠道微生物相互作用的高优先平台。最近,肠道菌群的图谱分析将IBD的发病机制与菌群各组成部分特征的改变相联系,进一步支持"肠道微生物和宿主相互作用的改变能形成IBD"这一观点。该文回顾性分析有关IBD患者体内微生物的研究文献,综述肠道微生态失衡对IBD的多方面影响,以动物模型和临床验证资料阐述不同的治疗方法改善肠道微生态变化的最新进展。
    Abstract: Inflammatory bowel disease is a chronic inflammation of the intestinal tract, which comprises two primary forms of Crohn's disease(CD) and ulcerative colitis(UC). Decades of studies have revealed that environmental factors, susceptibility genes, and gut microbiota are considered as the major determinants for the induction of IBD. The combination of factors has made IBD as an appropriate and a high-priority platform for studying host-microbiome interactions. More recently, profiling studies of the intestinal microbe have associated pathogenesis of IBD with characteristic alterations in the composition of the intestinal microbiota,reinforcing the viewpoint that IBD results from the altered interplays between the host and intestinal microbe. the studies of the gut flora in IBD were reviewed andthe multiple effects of intestinal microbiota-dysfunction on the IBD were described.The progress of intestinal microbiota alterations with different therapeutic methods in animal models and clinic trials were provided.
  • [1] Molodecky NA,Soon IS,Rabi DM,et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time,based on systematic review[J].Gastroenterology,2012, 142(1):46-54.
    [2] Dave M,Higgins PD,Middha S,et al. The human gut microbiome: current knowledge,challenges,and future directions[J].Transl Res,2012,160(4):246-257.
    [3] Huttenhower C,Kostic AD,Xavier RJ. Inflammatory bowel disease as a model for translating the microbiome[J]. Immunity,2014,40(6):843-854.
    [4] Morgan XC,Segata N,Huttenhower C. Biodiversity and functional genomics in the human microbiome[J]. Trends Genet,2013,29(1):51-58.
    [5] Scaldaferri F,Gerardi V,Lopetuso LR,et al. Gut microbial flora,prebiotics,and probiotics in IBD: their current usage and utility[J]. Biomed Res Int,2013,2013:435268.
    [6] Hooper LV,Littman DR,Macpherson AJ. Interactions between the microbiota and the immune system[J].Science,2012,336(6086):1268-1273.
    [7] Boudeau J,Glasser AL,Masseret E,et al. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease[J].Infect Immun,1999,67(9):4499-4509.
    [8] Rolhion N,Darfeuille-Michaud A. Adherent-invasive Escherichia coli in inflammatory bowel disease[J]. Inflamm Bowel Dis,2007,13(10):1277-1283.
    [9] Allen-Vercoe E,Jobin C. Fusobacterium and Enterobacteriaceae: important players for CRC?[J].Immunol Lett,2014,162(2PA):54-61.
    [10] Allen-Vercoe E,Strauss J,Chadee K. Fusobacterium nucleatum: an emerging gut pathogen?[J].Gut Microb,2011,2(5):294-298.
    [11] Ohkusa T,Okayasu I,Ogihara T,et al. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis[J]. Gut,2003,52(1):79-83.
    [12] Strauss J,Kaplan GG,Beck PL,et al. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host[J]. Inflamm Bowel Dis,2011,17(9):1971-1978.
    [13] Kostic AD,Chun E,Robertson L,et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment[J]. Cell Host Microb,2013,14(2):207-215.
    [14] Kitajima S,Morimoto M,Sagara E,et al. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice[J]. Exp Anim,2001,50(5):387-395.
    [15] Kamada N,Chen G,Núez G. A complex microworld in the gut: harnessing pathogen-commensal relations[J]. Nat Med,2012,18(8):1190-1191.
    [16] Llopis M,Antolin M,Carol M,et al. Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa[J]. Inflamm Bowel Dis,2009,15(2):275-283.
    [17] Varela E,Manichanh C,Gallart M,et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis[J]. Aliment Pharmacol Ther,2013,38(2):151-161.
    [18] Cadwell K,Patel KK,Maloney NS,et al. Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine[J]. Cell,2010,141(7):1135-1145.
    [19] Trojanowska D,Zwolinska-Wcislo M,Tokarczyk M,et al. The role of Candida in inflammatory bowel disease. Estimation of transmission of C. albicans fungi in gastrointestinal tract based on genetic affinity between strains[J]. Med Sci Monit,2010,16(10):CR451-457.
    [20] Iliev ID,Funari VA,Taylor KD,et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis[J]. Science,2012,336(6086):1314-1317.
    [21] Morgan XC,Tickle TL,Sokol H,et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment[J]. Genome Biol,2012,13(9):R79.
    [22] Atarashi K,Tanoue T,Oshima K,et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota[J]. Nature,2013,500(7461):232-236.
    [23] Duncan SH,Hold GL,Barcenilla A,et al.Roseburia intestinalis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces[J]. Int J Syst Evol Microbiol, 2002,52(Pt 5):1615-1620.
    [24] Khan KJ,Ullman TA,Ford A,et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and Meta-analysis[J]. Am J Gastroenterol,2011,106(4):661-673.
    [25] Lemon KP,Armitage GC,Relman DA,et al. Microbiota-targeted therapies: an ecological perspective[J]. Sci Transl Med,2012,4(137):137rv5.
    [26] Gevers D,Kugathasan S,Denson LA,et al. The treatment-naive microbiome in new-onset Crohn's disease[J]. Cell Host Microb,2014,15(3):382-392.
    [27] Wlodarska M,Willing B,Keeney KM,et al. Antibiotic treatment alters the colonic mucus layer and predisposes the host to exacerbated Citrobacter rodentium induced colitis[J]. Infect Immun,2011,79(4):1536-1545.
    [28] Damman CJ,Miller SI,Surawicz CM,et al. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation?[J].Am J Gastroenterol,2012,107(10):1452-1459.
    [29] Shahinas D,Silverman M,Sittler T,et al. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing[J]. MBio,2012,3(5):e00338-12.
    [30] Anderson JL,Edney RJ,Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease[J]. Aliment Pharmacol Ther,2012,36(6):503-516.
    [31] Morgan XC,Huttenhower C. Meta'omic analytic techniques for studying the intestinal microbiome[J]. Gastroenterology,2014,146(6):1437-1448.
  • [1] 刘胜, 陈敏, 凃远珍.  基于前置审核系统优化的三唑类抗真菌药与他汀类药物相互作用精细化审核 . 药学实践与服务, 2022, 40(2): 175-179. doi: 10.12206/j.issn.1006-0111.202109126
    [2] 邓子云, 沈祥国, 徐灿, 田泾.  注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗强直性脊柱炎疑致克罗恩病1例 . 药学实践与服务, 2020, 38(3): 286-288. doi: 10.12206/j.issn.1006-0111.201911045
    [3] 李安, 周小青, 孙阔, 杨谨如, 朱勇飞, 陆一鸣.  药物分子与靶蛋白相互作用的研究进展 . 药学实践与服务, 2019, 37(1): 1-4,31. doi: 10.3969/j.issn.1006-0111.2019.01.001
    [4] 卞莹莹, 王洁, 李安, 开国银, 陆一鸣.  炎症性肠病的药物治疗现状 . 药学实践与服务, 2017, 35(3): 197-200,228. doi: 10.3969/j.issn.1006-0111.2017.03.002
    [5] 黄瑾, 曾颖, 唐帆, 袁芳.  中药及其活性成分与氯吡格雷抗血小板聚集的相互作用 . 药学实践与服务, 2016, 34(5): 389-392,398. doi: 10.3969/j.issn.1006-0111.2016.05.002
    [6] 孙华君, 顾之睿, 车大钿, 高春辉, 于广军.  基于医嘱数据的肺炎住院儿童肠道微生态制剂应用的疗效分析 . 药学实践与服务, 2014, 32(6): 453-455,479. doi: 10.3969/j.issn.1006-0111.2014.06.013
    [7] 黄玉凤, 赵卫红, 黄弥娜, 刘敏.  规范用药指导，促进合理用药 . 药学实践与服务, 2008, (4): 304-307.
    [8] 高保安, 陈建明.  药物与白蛋白相互作用的研究进展 . 药学实践与服务, 2008, (4): 241-244.
    [9] 陈福喜, 曲申宁.  中西药物合用致不良相互作用及原因分析 . 药学实践与服务, 2001, (4): 251-253,250.
    [10] 尹玉琴, 陈振德, 蒋世新.  布美他尼与地高辛相互作用及药代动力学考察 . 药学实践与服务, 1997, (4): 224-225.
    [11] 陆忠贤, 屠世忠, 张紫洞.  利福平和苯妥英钠相互作用的重要性 . 药学实践与服务, 1990, (1): 27-27.
    [12] M.R.P.Hall.  老龄病人药物相互作用 . 药学实践与服务, 1989, (1): 38-40.
    [13] J.R.Dungore.  抗生素药物相互作用的体外微生物学研究 . 药学实践与服务, 1989, (1): 41-43.
    [14] 汤爱珍, 樊启荣.  异搏定和西米替丁药物相互作用 . 药学实践与服务, 1987, (4): 43-43.
    [15] 孙效东, 张志萍.  异搏定和地高辛相互作用 . 药学实践与服务, 1987, (2): 21-21.
    [16] 丁祯禄, 冯仰华.  两性霉素B和多粘菌素B相互作用的实验研究 . 药学实践与服务, 1985, (2): 79-79.
    [17] 苏开仲, 戴诗文.  药物相互作用文摘和评论 . 药学实践与服务, 1984, (1): 35-35.
    [18] 戴诗文, 张紫洞.  药物相互作用文摘和评论 . 药学实践与服务, 1984, (1): 46-46.
    [19] 刘海友, 郭步英, 张紫洞.  药物与食物的相互作用 . 药学实践与服务, 1984, (4): 44-46.
    [20] 戴诗文, 张紫洞.  药物相互作用文摘和评论 . 药学实践与服务, 1984, (1): 47-47.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3020
  • HTML全文浏览量:  214
  • PDF下载量:  576
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-11-13
  • 修回日期:  2015-03-17

肠道微生态与炎症性肠病

doi: 10.3969/j.issn.1006-0111.2015.05.001
  • 1. 第二军医大学药学院新药研究中心, 上海 200433
  • 2. 同济大学附属第十人民医院, 上海 200072
  • 3. 同济大学医学院, 上海 200092
  • 收稿日期: 2014-11-13
  • 修回日期: 2015-03-17

摘要: 炎症性肠病(inflammatory bowel disease,IBD)是一组病因未明、发病机制亦不明确的慢性肠道炎症性疾病,主要包括克罗恩病(Crohn's disease,CD)和溃疡性结肠炎(ulcerative colitis,UC)。近几十年的研究结果认为,其发病是环境、易感基因和肠道微生态3个要素相互作用的结果,且这些要素使IBD成为一种适合研究宿主与肠道微生物相互作用的高优先平台。最近,肠道菌群的图谱分析将IBD的发病机制与菌群各组成部分特征的改变相联系,进一步支持"肠道微生物和宿主相互作用的改变能形成IBD"这一观点。该文回顾性分析有关IBD患者体内微生物的研究文献,综述肠道微生态失衡对IBD的多方面影响,以动物模型和临床验证资料阐述不同的治疗方法改善肠道微生态变化的最新进展。

English Abstract

何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
引用本文: 何丽娟, 张军东, 安毛毛, 姜远英. 肠道微生态与炎症性肠病[J]. 药学实践与服务, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
shu
HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
Citation: HE Lijuan, ZHANG Jundong, AN Maomao, JIANG Yuanying. Gut microbiota and inflammatory bowel disease[J]. Journal of Pharmaceutical Practice and Service, 2015, 33(5): 385-388,422. doi: 10.3969/j.issn.1006-0111.2015.05.001
shu

    全文HTML

参考文献 (31)

目录

    /

    返回文章
    返回

    版权所有：《药学实践与服务》编辑委员会

    主管、主办: 中国人民解放军海军军医大学地址: 上海市杨浦区国和路325号邮政编码: 200433

    电话: （021）81871324,81871397 E-mail: yxsjzzs@163.com

    网站备案号 沪ICP备05003363号-1

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计